Clinical Trial Update: Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety [Phase 3]

View source ↗

Summary

Phase 3 randomized, double-blind, placebo-controlled study evaluating topical clobetasone butyrate 0.05% cream for eczema; study status is COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Clobetasone butyrate 0.05% cream (clobetasone butyrate)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Eczema | Phase 3 | Status: COMPLETED